C. Dakhil

发表

Metastasis of Benign Leiomyomas Outside the Uterus

S. Dakhil, N. Parker, C. Dakhil, 2018, Kansas journal of medicine.

Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice

D. Moore, S. Dakhil, K. Choucair, 2022, The oncologist.

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Edward S. Kim, M. Socinski, V. Velcheti, 2022, Nature Medicine.

Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603)

Thomas J. Smith, P. Novotny, R. Leon-Ferre, 2019, JNCI cancer spectrum.

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC

Edward S. Kim, C. Langer, J. Goldman, 2018, Front. Oncol..

Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series

D. Tindall, Zhifu Sun, K. Rowland, 2019, The American journal of hospice & palliative care.

Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience.

D. Moore, S. Dakhil, K. Choucair, 2022, Clinical Breast Cancer.

Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report

N. Haideri, Anup Kasi Loknath Kumar, C. Dakhil, 2014, Journal of Medical Case Reports.

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial

Michael C. Mosier, N. Vogelzang, N. Gabrail, 2017, Cancer management and research.

Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).

D. Carbone, Melissa L. Johnson, S. Ramalingam, 2020, Clinical lung cancer.

Pancreatic Mass is not always Adenocarcinoma

Bharat Malhotra, C. Dakhil, A. Rahal, 2015 .

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report of a Rare Leukemic Variant

W. Palko, A. Al-Obaidi, C. Dakhil, 2020 .

Undiagnosed Systemic Lupus Erythematosus Presenting as Hemophagocytic Lymphohistiocytosis

C. Dakhil, A. Rahal, Justin G Fernandez, 2015, Case reports in rheumatology.

Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

M. Socinski, V. Velcheti, D. Shames, 2019, Annals of Oncology.

Extrapulmonary small cell carcinoma: the University of Kansas experience and review of literature

P. Neupane, J. Wick, Megha Teeka Satyan, 2014, Medical Oncology.

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC).

M. Socinski, V. Velcheti, D. Fabrizio, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.

Edward S. Kim, M. Socinski, V. Velcheti, 2018 .

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rapidly Progressive and Fatal Disease without Aggressive Intervention

S. Mathur, C. Dakhil, L. Prochaska, 2013, Clinical medicine insights. Case reports.

APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.

Michael C. Mosier, Robert E. Smith, N. Gabrail, 2016, Future oncology.

ABOUND.70+: Safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).

Edward S. Kim, C. Langer, J. Goldman, 2017 .